Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice

Journal of Lipid Research

Volumn 56, Issue 7, 2015, Pages 1282-1295

  Thacker, Seth G ^a   Rousset, Xavier ^a   Esmail, Safiya ^a   Zarzour, Abdalrahman ^a   Jin, Xueting ^a   Collins, Heidi L ^b   Sampson, Maureen ^c   Stonik, John ^a   Demosky, Stephen ^a   Malide, Daniela A ^a   Freeman, Lita ^a   Vaisman, Boris L ^a   Kruth, Howard S ^a   Adelman, Steven J ^b   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Vascular Strategies LLC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; APOLIPOPROTEIN M; CHOLESTEROL; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CD36 ANTIGEN;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOB GENE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FEMALE; GENE; GENE EXPRESSION; HMGCR GENE; LDLR GENE; MOUSE; NONHUMAN; PCSK9 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; THROMBOCYTE COUNT; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; DEFICIENCY; ENZYMOLOGY; ERYTHROCYTE; ESTERIFICATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; HUMAN; LIPID DIET; LIVER; METABOLISM; PATHOLOGY; THROMBOCYTE; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; CHOLESTEROL; DIET, HIGH-FAT; ERYTHROCYTE COUNT; ERYTHROCYTES; ESTERIFICATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKOUT TECHNIQUES; HUMANS; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PLATELET COUNT;

EID: 84937123363     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M048629     Document Type: Article

References (82)

1. Kunnen, S., and M. Van Eck. 2012. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J. Lipid Res. 53: 1783-1799.
2. Schwartz, C. C., J. M. VandenBroek, and P. S. Cooper. 2004. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45: 1594-1607.
3. Czarnecka, H., and S. Yokoyama. 1996. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. J. Biol. Chem. 271: 2023-2028.
4. Schwartz, C. C., L. A. Zech, J. M. VandenBroek, and P. S. Cooper. 1993. Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate. J. Clin. Invest. 91: 923-938.
5. Shamburek, R. D., L. A. Zech, P. S. Cooper, J. M. Vandenbroek, and C. C. Schwartz. 1996. Disappearance of two major phosphatidylcholines from plasma is predominantly via LCAT and hepatic lipase. Am. J. Physiol. 271: E1073-E1082.
6. Chen, Z., S. P. Wang, M. L. Krsmanovic, J. Castro-Perez, K. Gagen, V. Mendoza, R. Rosa, V. Shah, T. He, S. J. Stout, et al. 2012. Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism. 61: 470-481.
7. Rousset, X., R. Shamburek, B. Vaisman, M. Amar, and A. T. Remaley. 2011. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Curr. Atheroscler. Rep. 13: 249-256.
8. Rousset, X., B. Vaisman, M. Amar, A. A. Sethi, and A. T. Remaley. 2009. Lecithin: cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16: 163-171.
9. Shamburek, R. D., L. Freeman, M. Sampson, R. Bakker-Arkema, B. Krause, B. Auerbach, R. Homan, A. Shamburek, C. Schwartz, M. Amar, et al. 2013. Human enzyme replacement therapy in a patient with familial lecithin cholesterol acyltransferase deficiency: rapid appearance of normal appearing HDL. Circulation. 128: A18673.
10. Kellner-Weibel, G., W. G. Jerome, D. M. Small, G. J. Warner, J. K. Stoltenborg, M. A. Kearney, M. H. Corjay, M. C. Phillips, and G. H. Rothblat. 1998. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler. Thromb. Vasc. Biol. 18: 423-431.
11. Warner, G. J., G. Stoudt, M. Bamberger, W. J. Johnson, and G. H. Rothblat. 1995. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem. 270: 5772-5778.
12. Nicholls, S. J., I. Sipahi, J. Andrews, K. Wolski, P. Schoenhagen, T. Crowe, M. Y. Desai, E. M. Tuzcu, and S. E. Nissen. 2006. Proatherogenic impact of the ACAT inhibitor pactimibe in patients with coronary artery disease and multiple risk factors: insights from the ACTIVATE study. Circulation. 114: II-224.
13. Hung, K. T., S. Z. Berisha, B. M. Ritchey, J. Santore, and J. D. Smith. 2012. Red blood cells play a role in reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 32: 1460-1465.
14. Lin, H. L., X. S. Xu, H. X. Lu, L. Zhang, C. J. Li, M. X. Tang, H. W. Sun, Y. Liu, and Y. Zhang. 2007. Pathological mechanisms and dose dependency of erythrocyte-induced vulnerability of atherosclerotic plaques. J. Mol. Cell. Cardiol. 43: 272-280.
15. Tziakas, D., G. Chalikias, A. Grapsa, T. Gioka, I. Tentes, and S. Konstantinides. 2012. Red blood cell distribution width: a strong prognostic marker in cardiovascular disease: is associated with cholesterol content of erythrocyte membrane. Clin. Hemorheol. Microcirc. 51: 243-254.
16. Tziakas, D. N., J. C. Kaski, G. K. Chalikias, C. Romero, S. Fredericks, I. K. Tentes, A. X. Kortsaris, D. I. Hatseras, and D. W. Holt. 2007. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J. Am. Coll. Cardiol. 49: 2081-2089.
17. Vayá, A., M. Martínez Triguero, E. Réganon, V. Vila, V. Martínez Sales, E. Solá, A. Hernández Mijares, and A. Ricart. 2008. Erythrocyte membrane composition in patients with primary hypercholesterolemia. Clin. Hemorheol. Microcirc. 40: 289-294. [Erratum. 2009. Clin. Hemorheol. Microcirc. 41: 149.]
18. Cooper, R. A., J. R. Durocher, and M. H. Leslie. 1977. Decreased fluidity of red cell membrane lipids in abetalipoproteinemia. J. Clin. Invest. 60: 115-121.
19. Holm, T. M., A. Braun, B. L. Trigatti, C. Brugnara, M. Sakamoto, M. Krieger, and N. C. Andrews. 2002. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood. 99: 1817-1824.
20. Shattil, S. J., J. S. Bennett, R. W. Colman, and R. A. Cooper. 1977. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J. Lab. Clin. Med. 89: 341-353.
21. Knöfler, R., T. Urano, T. Taminato, T. Yoshimi, T. Nakano, K. Nakajima, Y. Takada, and A. Takada. 1995. Daily variation of serum lipids in relation to the circadian rhythm of platelet aggregation in healthy male persons. Clin. Chim. Acta. 239: 109-119.
22. Shattil, S. J., R. Anaya-Galindo, J. Bennett, R. W. Colman, and R. Cooper. 1975. Platelet hypersensitivity induced by cholesterol incorporation. J. Clin. Invest. 55: 636-643.
23. Trigatti, B., H. Rayburn, M. Viñals, A. Braun, H. Miettinen, M. Penman, M. Hertz, M. Schrenzel, L. Amigo, A. Rigotti, et al. 1999. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl. Acad. Sci. USA. 96: 9322-9327.
24. Arai, T., F. Rinninger, L. Varban, V. Fairchild-Huntress, C. P. Liang, W. Chen, T. Seo, R. Deckelbaum, D. Huszar, and A. R. Tall. 1999. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. Proc. Natl. Acad. Sci. USA. 96: 12050-12055.
25. Braun, A., B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger. 2002. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90: 270-276.
26. Kozarsky, K. F., M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader. 2000. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20: 721-727.
27. Van Eck, M., J. Twisk, M. Hoekstra, B. T. Van Rij, C. A. C. Van der Lans, I. S. T. Bos, J. K. Kruijt, F. Kuipers, and T. J. C. Van Berkel. 2003. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J. Biol. Chem. 278: 23699-23705.
28. Yu, H., W. Zhang, P. G. Yancey, M. J. Koury, Y. Zhang, S. Fazio, and M. F. Linton. 2006. Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice. Arterioscler. Thromb. Vasc. Biol. 26: 150-156.
29. Ma, K., T. Forte, J. D. Otvos, and L. Chan. 2005. Differential additive effects of endothelial lipase and scavenger receptor-class B type I on high-density lipoprotein metabolism in knockout mouse models. Arterioscler. Thromb. Vasc. Biol. 25: 149-154.
30. Barter, P. J., G. J. Hopkins, and L. Gorjatschko. 1985. Lipoprotein substrates for plasma cholesterol esterification: influence of particle size and composition of the high density lipoprotein subfraction 3. Atherosclerosis. 58: 97-107.
31. Vaisman, B. L., H. G. Klein, M. Rouis, A. M. Berard, M. R. Kindt, G. D. Talley, S. M. Meyn, R. F. Hoyt, Jr., S. M. Marcovina, J. J. Albers, et al. 1995. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J. Biol. Chem. 270: 12269-12275.
32. Lambert, G., N. Sakai, B. L. Vaisman, E. B. Neufeld, and B. Marteyn. 2001. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J. Biol. Chem. 276: 15090-15098.
33. Miettinen, H. E., H. Rayburn, and M. Krieger. 2001. Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J. Clin. Invest. 108: 1717-1722.
34. Maugeais, C., U. J. Tietge, K. Tsukamoto, J. M. Glick, and D. J. Rader. 2000. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J. Lipid Res. 41: 1673-1679.
35. Mweva, S., J. L. Paul, M. Cambillau, D. Goudouneche, P. Beaune, A. Simon, and N. Fournier. 2006. Comparison of different cellular models measuring in vitro the whole human serum cholesterol efflux capacity. Eur. J. Clin. Invest. 36: 552-559.
36. de la Llera-Moya, M., D. Drazul-Schrader, B. F. Asztalos, M. Cuchel, D. J. Rader, and G. H. Rothblat. 2010. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30: 796-801.
37. Kempen, H. J., M. Gomaraschi, S. E. Bellibas, S. Plassmann, B. Zerler, H. L. Collins, S. J. Adelman, L. Calabresi, and P. L. Wijngaard. 2013. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J. Lipid Res. 54: 2341-2353.
38. Alexander, E. T., C. Vedhachalam, S. Sankaranarayanan, M. de la Llera-Moya, G. H. Rothblat, D. J. Rader, and M. C. Phillips. 2011. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol. 31: 320-327.
39. Matic, G. B., G. Rothe, and G. Schmitz. 2001. Flow cytometric analysis of reticulated platelets. Curr. Protoc. Cytom. 17: 7.10.1-7.10.6.
40. Dole, V. S., J. Matuskova, E. Vasile, A. Yesilaltay, W. Bergmeier, M. Bernimoulin, D. D. Wagner, and M. Krieger. 2008. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 1111-1116.
41. Basso, F., M. J. Amar, E. M. Wagner, B. Vaisman, B. Paigen, S. Santamarina-Fojo, and A. T. Remaley. 2006. Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. Biochem. Biophys. Res. Commun. 351: 398-404.
42. Schneider, C. A., W. S. Rasband, and K. W. Eliceiri. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 9: 671-675.
43. Kruth, H. S., and D. L. Fry. 1984. Histochemical detection and differentiation of free and esterified cholesterol in swine atherosclerosis using filipin. Exp. Mol. Pathol. 40: 288-294.
44. Carr, T. P., R. L. Hamilton, Jr., and L. L. Rudel. 1995. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J. Lipid Res. 36: 25-36.
45. Joyce, C., K. Skinner, R. A. Anderson, and L. L. Rudel. 1999. Acylcoenzyme A:cholesteryl acyltransferase 2. Curr. Opin. Lipidol. 10: 89-95.
46. Temel, R. E., L. Hou, L. L. Rudel, and G. S. Shelness. 2007. ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. J. Lipid Res. 48: 1618-1627.
47. Rigotti, A., B. L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger. 1997. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. USA. 94: 12610-12615.
48. Jonas, A. 1998. Regulation of lecithin cholesterol acyltransferase activity. Prog. Lipid Res. 37: 209-234.
49. Forte, T. M., G. Subbanagounder, J. A. Berliner, P. J. Blanche, A. O. Clermont, Z. Jia, M. N. Oda, R. M. Krauss, and J. K. Bielicki. 2002. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid Res. 43: 477-485.
50. Jian, B., M. de la Llera-Moya, Y. Ji, N. Wang, M. C. Phillips, J. B. Swaney, A. R. Tall, and G. H. Rothblat. 1998. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J. Biol. Chem. 273: 5599-5606.
51. Robinet, P., Z. Wang, S. L. Hazen, and J. D. Smith. 2010. A simple and sensitive enzymatic method for cholesterol quantification in macrophages and foam cells. J. Lipid Res. 51: 3364-3369.
52. Covey, S. D., M. Krieger, W. Wang, M. Penman, and B. L. Trigatti. 2003. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23: 1589-1594.
53. Duewell, P., H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nunez, M. Schnurr, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 464: 1357-1361.
54. Rajama¨ki, K., J. Lappalainen, K. O¨örni, E. Va¨lima¨ki, S. Matikainen, P. T. Kovanen, and K. K. Eklund. 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE. 5: e11765.
55. Korporaal, S. J. A., I. Meurs, A. D. Hauer, R. B. Hildebrand, M. Hoekstra, H. T. Cate, D. Praticò, J-W. N. Akkerman, T. J. C. Van Berkel, J. Kuiper, et al. 2011. Deletion of the high-density lipoprotein receptor scavenger receptor bi in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler. Thromb. Vasc. Biol. 31: 34-42.
56. Trigatti, B., S. Covey, and A. Rizvi. 2004. Scavenger receptor class B type I in high-density lipoprotein metabolism, atherosclerosis and heart disease: lessons from gene-targeted mice. Biochem. Soc. Trans. 32: 116-120.
57. VanderLaan, P. A., C. A. Reardon, R. A. Thisted, and G. S. Getz. 2009. VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. J. Lipid Res. 50: 376-385.
58. Carmena, R., P. Duriez, and J-C. Fruchart. 2004. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 109: III-2-III-7.
59. Barter, P. J., S. Nicholls, K-A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
60. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232.
61. Feng, H., and X. A. Li. 2009. Dysfunctional high-density lipoprotein. Curr. Opin. Endocrinol. Diabetes Obes. 16: 156-162.
62. Hewing, B., K. J. Moore, and E. A. Fisher. 2012. HDL and cardiovascular risk. Circ. Res. 111: 1117-1120.
63. Otocka-Kmiecik, A., D. P. Mikhailidis, S. J. Nicholls, M. Davidson, J. Rysz, and M. Banach. 2012. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51: 314-324.
64. Smith, J. D. 2010. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol. 30: 151-155.
65. Barter, P. J., and K. A. Rye. 2012. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53: 1755-1766.
66. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub; AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
67. Hopewell, J. C., A. Offer, S. Parish, R. Haynes, J. Li, L. Jiang, M. Lathrop, J. Armitage, R. Collins, and H-T. C. Group. 2012. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE. Eur. Heart J. 33: 445.
68. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
69. Yesilaltay, A., M. G. Morales, L. Amigo, S. Zanlungo, A. Rigotti, S. L. Karackattu, M. H. Donahee, K. F. Kozarsky, and M. Krieger. 2006. Effects of hepatic expression of the high-density lipoprotein receptor SR-BI on lipoprotein metabolism and female fertility. Endocrinology. 147: 1577-1588.
70. Francone, O. L., M. Haghpassand, J. A. Bennett, L. Royer, and J. McNeish. 1997. Expression of human lecithin:cholesterol acyltransferase in transgenic mice: effects on cholesterol efflux, esterification, and transport. J. Lipid Res. 38: 813-822.
71. Huszar, D., M. L. Varban, F. Rinninger, R. Feeley, T. Arai, V. Fairchild-Huntress, M. J. Donovan, and A. R. Tall. 2000. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler. Thromb. Vasc. Biol. 20: 1068-1073.
72. Ji, Y., B. Jian, N. Wang, Y. Sun, M. L. Moya, M. C. Phillips, G. H. Rothblat, J. B. Swaney, and A. R. Tall. 1997. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 272: 20982-20985.
73. Tabas, I., S. Marathe, G. A. Keesler, N. Beatini, and Y. Shiratori. 1996. Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis. J. Biol. Chem. 271: 22773-22781.
74. Fazio, S., A. S. Major, L. L. Swift, L. A. Gleaves, M. Accad, M. F. Linton, and R. V. Farese. 2001. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest. 107: 163-171.
75. Nofer, J. R., M. F. Brodde, and B. E. Kehrel. 2010. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 37: 726-735.
76. Nofer, J. R., G. Herminghaus, M. Brodde, E. Morgenstern, S. Rust, T. Engel, U. Seedorf, G. Assmann, H. Bluethmann, and B. E. Kehrel. 2004. Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J. Biol. Chem. 279: 34032-34037.
77. Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508-519.
78. Föger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, et al. 1999. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274: 36912-36920.
79. El Bouhassani, M., S. Gilibert, M. Moreau, F. Saint-Charles, M. Treguier, F. Poti, M. J. Chapman, W. Le Goff, P. Lesnik, and T. Huby. 2011. Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis. J. Biol. Chem. 286: 17227-17238.
80. Bérard, A. M., B. Föger, A. Remaley, R. Shamburek, B. L. Vaisman, G. Talley, B. Paigen, R. F. Hoyt, Jr., S. Marcovina, H. B. Brewer, Jr., et al. 1997. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3: 744-749.
81. Mehlum, A., M. Muri, T. A. Hagve, L. A. Solberg, and H. Prydz. 1997. Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS. 105: 861-868.
82. Hoeg, J. M., S. Santamarina-Fojo, A. M. Bérard, J. F. Cornhill, E. E. Herderick, S. H. Feldman, C. C. Haudenschild, B. L. Vaisman, R. F. Hoyt, S. J. Demosky, et al. 1996. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA. 93: 11448-11453.